GH Research PLC
NASDAQ:GHRSBiotechnology
-$0.04 today
- Market cap
- $1.25B
- Beta
- 1.31
- P/E (TTM)
- -23.8
- EPS (TTM)
- -$0.91
Volume 0.46M
Average 0.23M
GHRS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
GH Research PLCNASDAQ: GHRS
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $18.97M (cash outflow) rose 75.4% year over year, ahead of the +34.0% change in trailing-twelve-month net income. Sequentially, it rose 34.2% from the prior quarter. Over 3 fiscal years it compounded at +29.0% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$81.48M (+68.8%) for the fiscal year ending Dec 2026, a step up from the +23.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.97M+34.2% QoQ
- Last fiscal yearDec 2025
- -$48.26M+23.9% YoY
- LTMMar 2026
- -$56.41M+34.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +75.4% | +113.7% | +38.3 pp |
| 1 year | +23.9% | +68.8% | +45.0 pp |
| 3-year CAGR | +29.0% | +51.1% | +22.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (48.26M) USD
- Year-over-year change
- -23.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (48.26M) | -23.9% |
| FY2024 | 2024-12-31 | (38.96M) | -9.5% |
| FY2023 | 2023-12-31 | (35.59M) | -58.5% |
| FY2022 | 2022-12-31 | (22.46M) | -144.0% |
| FY2021 | 2021-12-31 | (9.2M) | — |
Net Income vs competitors
How GHRS compares with its peers on the latest reported figures
- GHRS's LTM Mar 2026 net income of $56.41M is the 8th largest of the 9 companies compared; the peer median is $210.94M.
- Its year-over-year change of +34.0% is the 4th highest of 7, against a peer median of +26.1%.
- Over three fiscal years its annual growth of +29.0% compares with a peer median of +39.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $108.22B | — | +109.1% | — | |
| LTM Jun 2026 | $586.84M | -23.5% | +9.0% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $337.48M | +100.8% | +47.9% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $222.39M | -13.8% | +21.9% | — |
| LTM Mar 2026 | $199.48M | +146.3% | +75.1% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $107.28M | +34.6% | +118.7% | 536.4% |
| LTM Mar 2026 | $74.31M | +17.6% | +31.7% | — | |
| LTM Mar 2026 | $56.41M | +34.0% | +29.0% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M | — | +20.7% | — |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding GHRS) | $210.94M | +26.1% | +39.8% | 536.4% | |
Competitors are the stored peer set for GHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.2M) | (22.46M) | (35.59M) | (38.96M) | (48.26M) |
| Depreciation & Amortization | 19K | 47K | 315K | 315K | 335K |
| Deferred Income Tax | (5.92M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 366K | 1.67M | 2.29M | 1.17M | 0 |
| Change in Working Capital | (559K) | 2.16M | 1.65M | 188K | (3.09M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (559K) | 2.16M | 1.65M | 188K | (3.09M) |
| Other Non-Cash Items | 9K | (7.62M) | (2M) | (5M) | 7.46M |
| Operating Cash Flow | (15.28M) | (26.2M) | (33.34M) | (42.29M) | (43.55M) |
| Capital Expenditures | (104K) | (67K) | (100K) | (49K) | (121K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | (84.62M) | (54M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 65.18M | 46.29M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (104K) | (84.69M) | (54.1M) | 65.14M | 46.17M |
| Debt Repayment | 0 | 0 | (219K) | (304K) | 0 |
| Common Stock Issued | 309.2M | 0 | 15K | 0 | 139.85M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (22.75M) | 0 | 0 | 0 | (197K) |
| Financing Cash Flow | 286.45M | 0 | (204K) | (304K) | 139.65M |
| Effect of Forex Changes | (179K) | 66K | 105K | (175K) | 3.19M |
| Net Change in Cash | 270.88M | (110.82M) | (87.54M) | 22.37M | 145.46M |
| Free Cash Flow | (15.39M) | (26.27M) | (33.44M) | (42.33M) | (43.67M) |
GH Research PLC
NASDAQ:GHRS
Intrinsic Alpha fair value
Locked
Current Price
$18.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.